A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)

• Auteurs principaux: Taweegrit Siripongboonsitti (Auteur), Kriangkrai Tawinprai (Auteur), Panisadee Avirutnan (Auteur), Kunlakanya Jitobaom (Auteur), Prasert Auewarakul (Auteur)
• Format: Livre
• Publié: Elsevier, 2024-05-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Background: The efficacy of the viral clearance and clinical outcomes of favipiravir (FPV) in outpatients being treated for coronavirus disease 2019 (COVID-19) is unclear. Ivermectin (IVM), niclosamide (NCL), and FPV demonstrated synergistic effects in vitro for exceed 78% inhibiting severe acute re...